Zhang Mingzhen, Yang Chunhua, Yan Xiangji, Sung Junsik, Garg Pallavi, Merlin Didier
Institute of Medical Engineering, Department of Biophysics, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi, 710061, China.
Institute for Biomedical Sciences, Center for Diagnostics and Therapeutics, Digestive Disease Research Group, Georgia State University, Atlanta, Georgia, 30302, United States.
Adv Ther (Weinh). 2019 Dec;2(12). doi: 10.1002/adtp.201900129. Epub 2019 Sep 18.
A biocompatible natural nanoparticle drug delivery system that has specific cancer-targeting function holds vast promise for cancer therapy. Here, a fucoidan/poly-lysine-functionalized layer-by-layer ginger-derived lipid vector (LbL-GDLV) was designed to target P-selectin (overexpressed by endothelial cells) and deliver a loaded drug into vascularized colon cancer. , LbL-GDLVs selectively bound to P-selectin, and the degradation of the fucoidan outer layer in a milieu similar to the cancer microenvironment resulted in rapid attachment of the cancer cell and internalization of the remaining positively charged poly-lysine coated-GDLVs. Upon enzymolysis of the poly-lysine layer inside the cancer cell, the GDLV core released loaded doxorubicin (Dox) which had the expected effects. bio-distribution studies showed that intravenously injected LbL-GDLVs exhibited enhanced accumulation at the vascularized tumor site (~ 4.4-fold higher than control vesicles), presumably due to P-selectin-mediated targeting plus the enhanced permeability and retention effect (EPR). In two animal models used to screen anti-cancer efficacy (Luc-HT-29 and HCT-116 xenografts), Dox-loaded LbL-GDLVs (LbL-GDLVs/Dox) significantly inhibited tumor growth and demonstrated much better therapeutic efficiency than free Dox. More importantly, LbL-GDLVs/Dox exhibited excellent biocompatibility, and LbL-GDLVs encapsulation largely reduced the cardiotoxicity of free Dox and avoided the notorious drug resistance of colon cells against free Dox. Together, these findings demonstrate the potential of our newly designed and highly biocompatible plant-derived LbL nanoparticles and their precise colon cancer drug delivery function.
一种具有特定癌症靶向功能的生物相容性天然纳米颗粒药物递送系统在癌症治疗方面具有广阔前景。在此,设计了一种岩藻依聚糖/聚赖氨酸功能化的逐层生姜衍生脂质载体(LbL-GDLV),以靶向P-选择素(内皮细胞过表达)并将负载的药物递送至血管化的结肠癌中。LbL-GDLV选择性地与P-选择素结合,在类似于癌症微环境的环境中岩藻依聚糖外层的降解导致癌细胞快速附着以及剩余带正电荷的聚赖氨酸包被的GDLV内化。在癌细胞内聚赖氨酸层被酶解后,GDLV核心释放出具有预期效果的负载阿霉素(Dox)。生物分布研究表明,静脉注射的LbL-GDLV在血管化肿瘤部位的积累增强(比对照囊泡高约4.4倍),这可能是由于P-选择素介导的靶向作用加上增强的渗透和滞留效应(EPR)。在用于筛选抗癌疗效的两种动物模型(Luc-HT-29和HCT-116异种移植模型)中,负载Dox的LbL-GDLV(LbL-GDLV/Dox)显著抑制肿瘤生长,并且显示出比游离Dox更好的治疗效果。更重要的是,LbL-GDLV/Dox表现出优异的生物相容性,并且LbL-GDLV包封在很大程度上降低了游离Dox的心脏毒性,并避免了结肠细胞对游离Dox的耐药性。总之,这些发现证明了我们新设计的、具有高度生物相容性的植物衍生LbL纳米颗粒的潜力及其精确的结肠癌药物递送功能。